Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host cells susceptible to Dengue virus serotype 2 (DENV-2) infection primarily include cells of the myeloid lineage, such as monocytes, macrophages, and dendritic cells, which are considered the principal targets in vivo (PubMed: 11160744). These cells express various attachment factors and receptors, most notably DC-SIGN (CD209), heparan sulfate proteoglycans, and the mannose receptor, which facilitate viral entry via receptor-mediated endocytosis (PubMed: 12502850). Upon entry, the virus utilizes the host cell's endoplasmic reticulum and translation machinery to replicate its positive-sense RNA genome and assemble new virions (Nature Reviews Microbiology). The infection of these cells is a critical step in the pathogenesis of Dengue fever and its more severe forms, Dengue Hemorrhagic Fever and Dengue Shock Syndrome, which are characterized by a 'cytokine storm' and increased vascular permeability (NIH: StatPearls). Therapeutic interventions targeting these cells often involve small molecule inhibitors of viral proteins like the NS5 polymerase or host-targeted agents like alpha-glucosidase inhibitors (e.g., Celgosivir) that prevent proper viral protein folding (PubMed: 24501055). A significant challenge in treating these cells is the risk of antibody-dependent enhancement (ADE), where non-neutralizing antibodies facilitate viral entry into Fc-receptor-bearing cells, potentially worsening the infection (Wikipedia). Additionally, hepatocytes and endothelial cells can also be infected, contributing to liver dysfunction and vascular leakage (Journal of Virology).
Drugs targeting this system typically function by inhibiting viral enzymes (e.g., NS5 polymerase, NS3 protease) within the host cell, blocking viral entry via host receptors like DC-SIGN, or modulating host pathways such as alpha-glucosidase-mediated protein folding (PubMed: 24501055, 12502850).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host cells susceptible to Dengue virus serotype 2 infection.